论文部分内容阅读
目的:探讨荆花胃康胶丸联合三联疗法治疗幽门螺杆菌相关十二指肠溃疡的临床疗效。方法:采用前瞻性随机对照临床研究,于2014年1月—2014年12月对将收治的124例伴有Hp感染的十二指肠溃疡患者按照数字表法随机分为研究组和对照组,每组各62例,其中对照组给予标准三联疗法进行治疗,而研究组则在上述三联治疗的基础上给予荆花胃康胶丸,比较两组临床疗效、Hp根除率及不良反应发生率。结果:研究组患者的幽门螺杆菌清除率(88.71%)明显高于对照组(70.97%)(χ2=6.06,P<0.05)。研究组患者在的溃疡愈合总有效率(91.94%)明显高于对照组(77.42%)(χ2=5.03,P<0.05)。研究组患者在的临床症状改善总有效率(96.77%)明显高于对照组(87.10%)(χ2=3.92,P<0.05)。结论:荆花胃康胶丸联合三联疗法治疗幽门螺杆菌相关十二指肠溃疡的临床疗效明显高于标准三联疗法,可以有效根除Hp感染,值得临床推广使用。
Objective: To investigate the clinical efficacy of Jinghua Weikang capsule combined with triple therapy in the treatment of Helicobacter pylori associated duodenal ulcer. Methods: A prospective randomized clinical trial was conducted. From January 2014 to December 2014, 124 patients with duodenal ulcer associated with Hp infection were randomly divided into study group and control group according to the digital meter method. Each group of 62 cases, of which the control group given standard triple therapy for treatment, while the study group is based on the triple therapy given Jinghua Weikang capsule, the clinical efficacy, Hp eradication rate and incidence of adverse reactions. Results: The Helicobacter pylori clearance rate (88.71%) in the study group was significantly higher than that in the control group (70.97%) (χ2 = 6.06, P <0.05). The total effective rate of ulcer healing (91.94%) in study group was significantly higher than that in control group (77.42%) (χ2 = 5.03, P <0.05). The total effective rate (96.77%) in the study group was significantly higher than that in the control group (87.10%) (χ2 = 3.92, P <0.05). Conclusion: The clinical efficacy of Jinghuaweikang capsule combined with triple therapy in the treatment of Helicobacter pylori-associated duodenal ulcer is significantly higher than that of standard triple therapy, which can effectively eradicate Hp infection and is worthy of clinical promotion.